VBI Vaccines announces positive interim data from phase 1 study of CMV vaccine
VBI Vaccines announced positive results from a planned, interim data read-out from a Phase 1 study of its preventative cytomegalovirus vaccine. The vaccine was well tolerated at all doses, with no safety signals. The vaccine induced antibody responses against the CMV glycoprotein B antigen. July 27, 2017